New Paradigms for Advanced Prostate Cancer

Reviews in Urology

Daniel P Petrylak¹ 

[1]Department of Medicine, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY

关键词: Prostate cancer;    Hormone-refractory prostate cancer;    Androgen-independent prostate cancer;    Docetaxel;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

In men with metastatic hormone-refractory prostate cancer, androgen blockade produces dramatic and rapid declines in prostate-specific antigen (PSA), bone pain, and urinary tract obstruction. Nevertheless, there have been limited options with at best palliative results for patients who progress despite a castrate testosterone level. This paradigm changed in 2004 with the publication of 2 randomized clinical trials that demonstrated a 20% to 24% survival benefit for docetaxel-based therapy when compared to mitoxantrone and prednisone, data that supported US Food and Drug Administration approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer. This article reviews the preliminary data and the timing and sequencing implications of ongoing clinical trials. Studies are evaluating the combination of docetaxel with agents that target bone, tumor vasculature, and the vitamin D receptor as well as second-line agents, such as satraplatin. The role of immune therapy is also evolving, and further studies will define the optimal timing of chemotherapy with immune therapy.

【 授权许可】

Unknown